• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Animi-3(R) Clinical Trial for Cardiovascular Risk Reduction and Cognition Begins With Leading Medical Researcher From Tufts University

Posted on: Tuesday, 8 November 2005, 18:00 CST

GORDONSVILLE, Va., Nov. 8 /PRNewswire/ -- PBM Pharmaceuticals, Inc. (http://www.pbmpharmaceuticals.com/), the maker of Animi-3(R), announced today that it is conducting a clinical trial for cardiovascular risk reduction and cognition by a leading heart disease specialist. Animi-3 is a prescription- only product with specially formulated and highly refined omega-3 fatty acids. Animi-3 also contains the B vitamins: folic acid, B6, and B12. The clinical study is a six-month, double-blind, randomized, placebo-controlled trial in 75 subjects ages 55-80 years with no prior history of dementia.

The study started in September 2005 and is being conducted by Ernst J. Schaefer, M.D., of Cardiovascular Research Associates, in Boston, MA. Dr. Schaefer is also a Professor of Medicine at Tufts University School of Medicine.

"We believe subjects receiving the active supplement [Animi-3] will have significantly greater decreases in triglycerides, homocysteine, and small dense LDL, and greater increases in large HDL than those receiving the placebo," said Dr. Schaefer. "We are also studying the effects of this supplement on levels of C-Reactive Protein as well as measures of cognitive function, including memory and executive function."

Dr. Barbara Levine, Weill Medical College of Cornell University, is an expert on nutritional interactions between genetics and the prevention of cardiovascular disease, diabetes, and cancer, as well as the optimal diet for cognitive function and visual acuity in young children.

"The ingredients in Animi-3 benefit cardiovascular disease, cognition, and rheumatoid arthritis," said Dr. Levine, who was involved with the launch of the product. "Scientists and clinicians at Cornell University are actively prescribing the product and following up with patients on Animi-3."

Jack Schramm, EVP of PBM Pharmaceuticals and co-creator of Animi-3, is equally excited about the groundbreaking product and upcoming clinical trial.

"Studies published in peer-reviewed journals have reported that patients with cardiovascular disease, diabetes, rheumatoid arthritis, and depression may be deficient in omega-3 fatty acids, folic acid, and vitamins B6 and B12," said Schramm. "Animi-3 provides doctors with a means of addressing probable deficiencies in these vital nutrients."

"We are very happy to be working with Dr. Schaefer," added Jim McGrath, PBM EVP of Regulatory Affairs and co-creator of Animi-3. "He is a renowned expert in the areas of cardiovascular risk, lipoproteins, and nutrition. He is the perfect investigator to further explore the health benefits of Animi-3."

For more information, visit http://www.animi-3.com/.

Contact: Joe Shields, Director of Public Relations, (800) 959-2066 ext. 131, or jshields@pbmproducts.com

PBM Pharmaceuticals, Inc.

CONTACT: Joe Shields, Director of Public Relations of PBMPharmaceuticals, Inc., +1-800-959-2066 ext. 131, or jshields@pbmproducts.com

Web site: http://www.animi-3.com/http://www.pbmpharmaceuticals.com/

Source: PRNewswire

More News in this Category